Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objectives: To describe a multicenter experience of percutaneous transcatheter pulmonary valve replacement (TPVR) using the Edwards SAPIEN S3 valve without the use of a prior stent ("pre-stenting").
Background: The SAPIEN S3 and XT valves have durable cobalt-chromium stent frames which may allow for TPVR in large diameter dysfunctional right ventricular outflow tracts (RVOTs) without pre-stenting the landing zone.
Methods: A retrospective review was performed of all patients with Congenital Heart Disease and dysfunctional RVOT who underwent TPVR using the SAPIEN valve without the use of a pre-stent. Imaging data, procedural elements, and clinical follow-up data were collected to evaluate short and intermediate-term results.
Results: Fifty-seven patients underwent percutaneous placement of the SAPIEN valve in the pulmonary position without the use of pre-stenting. The anatomical substrate varied: native RVOTs (n = 41), conduits (n = 10), and bioprosthetic valves (n = 6). There were no cases in which the valve could not be implanted and no cases of valve embolization or misplacement. On follow-up (range 1 month to 2.2 years, median 5.3 months), no patients had significant obstruction or regurgitation around the valve. There were no frame fractures. There were no procedural deaths. Major complications included severe aortic compression (n = 1) requiring surgical explantation and tricuspid valve injury requiring surgical intervention (n = 2).
Conclusions: This limited multi-institutional experience demonstrates that the SAPIEN valve can be used for TPVR without the use of a pre-stent without medium-term risk of frame fracture, paravalvar leak, or embolization. Longer term follow-up is required to fully assess this method.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ccd.27932 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The ABC Bicuspid Sizing Protocol for SAPIEN 3 Balloon-Expandable Valves.
Struct Heart
September 2025
Division of Cardiology and Cardiac Surgery, McMaster University and Hamilton Health Sciences, Hamilton, Canada.
Background: The computed tomography selection of patients with bicuspid aortic stenosis for treatment with balloon-expandable valve (BEV) transcatheter aortic valve replacement (TAVR) is uncertain. We therefore evaluated a novel sizing algorithm for SAPIEN 3 BEV.
Methods: A prospective single-center registry from February 2020 to May 2024 including patients with bicuspid aortic stenosis treated with TAVR (and surgical aortic valve replacement starting in September 2022).
Ablation of ventricular tachycardia originating from the lower and septal portion of aortic prosthesis following transcatheter aortic valve replacement: a case report.
Eur Heart J Case Rep
August 2025
Division of Cardiovascular Medicine, Nouvel Hôpital Civil, Strasbourg University Hospital, BP 426, Strasbourg 67091, France.
Background: The number of transcatheter aortic valve replacement (TAVR) procedures is steadily increasing, and although its main complications are well documented, ventricular arrhythmias (VAs) following TAVR remain infrequently reported in the literature. We present a rare case of ventricular tachycardia (VT) occurring late after TAVR, originating from the lower portion of the prosthesis at the interventricular septum.
Case Summary: An 82-year-old Caucasian man presented with recurrent episodes of lipothymia and VT occurring late after undergoing TAVR.
Guiding Early Management in Severe Mitral Stenosis with Extensive Mitral Annular Calcification: A Transseptal ViMAC Case.
Am J Cardiol
August 2025
Department of Cardiac, Thoracic, and Vascular Sciences and Public Health, University of Padua, Italy. Electronic address:
Mitral annular calcification (MAC) related mitral stenosis (MS) presents a significant therapeutic challenge, especially in patients considered high-risk or inoperable.Transcatheter mitral valve replacement (TMVR) has emerged as an alternative, but the procedure remains technically demanding due to anatomical complexities and the risk of complications. We report the case of a 72 year-old man with severe MAC and MS, who successfully underwent TMVR using a 29 mm Edwards Sapien 3 valve.
View Article and Find Full Text PDFComparative 30-day Echocardiographic Outcomes of Myval versus Sapien and Evolut THVs: Insights from LANDMARK Trial.
Eur Heart J Cardiovasc Imaging
August 2025
Centre for Cardiovascular Medicine and Devices, William Harvey Research Institute, Queen Mary University of London and Barts Heart Centre, London, UK.
Introduction: Several factors, including device design, annulus size, and sizing strategies, influence transcatheter heart valve (THV) hemodynamic outcomes in patients with aortic stenosis(AS). This substudy evaluates early (30-day) echocardiographic outcomes of the Myval, Sapien, and Evolut THV series, focusing on hemodynamic performance and valve durability.
Methodology: The LANDMARK trial is a prospective, randomised, multicentre, open-label, non-inferiority trial comparing 384 patients implanted with Myval THV series to 384 receiving Sapien and Evolut THV series.
Mid-Term Outcomes of Balloon-Expandable Aortic Valve-in-Valve Replacement in the United States.
JACC Cardiovasc Interv
August 2025
Division of Cardiothoracic Surgery, Washington University in St. Louis, St. Louis, Missouri, USA.
Background: Aortic valve-in-valve (AViV) replacement for is approved for patients with degenerated surgical valves at high or prohibitive surgical risk, mostly on the basis of small series with short-term follow-up.
Objectives: The aim of this study was to analyze the outcomes of AViV therapy using contemporary balloon-expandable valves (BEVs) in a large series with mid-term outcomes.
Methods: BEV AViV patients (June 2015 to December 2023) in the Society for Thoracic Surgeons (STS)/American College of Cardiology TVT (Transcatheter Valve Therapy) Registry were propensity matched to native transcatheter aortic valve replacement (TAVR) patients.